Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences (NASDAQ: SSKN) reports significant success with its Elevate 360 (E360) consulting services platform, which helps partner clinics optimize their XTRAC laser treatment operations. The program focuses on implementing best practices in marketing, reimbursement, and patient retention.

Since early 2025, 99 out of 844 clinics have adopted E360, achieving an average 7% year-over-year growth. A notable case study showed one partner's revenue contribution to STRATA increasing from $10,500 in H1 2024 to $61,800 in H1 2025, while expanding from 2 to 9 clinics after implementing E360.

The program helps clinics optimize patient referrals, insurance reimbursement, scheduling, and follow-up visits, particularly beneficial with recent reimbursement improvements for vitiligo and auto-immune skin conditions.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced a $2.42 million registered direct offering of common stock. The company will sell 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.

The offering, expected to close around September 4, 2025, is being conducted with institutional investors, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. STRATA plans to use the proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement previously declared effective by the SEC.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Dr. Dolev Rafaeli will deliver a corporate overview presentation at the event, which takes place September 8-10, 2025 at the Lotte New York Palace Hotel.

The presentation will be available on demand starting September 5, 2025 at 7:00 AM ET for registered conference participants. Investors can request one-on-one meetings through the conference registration portal.

STRATA Skin Sciences (NASDAQ: SSKN) has affirmed its strong patent portfolio position for combination therapies using its XTRAC excimer laser with JAK inhibitors, systemic and biologic drugs. The company holds three key patents that protect the combined use of their technology with various therapeutic agents for treating dermatologic conditions.

The company is working with CMS to implement expanded CPT codes that would cover all inflammatory and autoimmune skin conditions, potentially tripling their addressable market by January 2026. This expansion includes conditions like vitiligo, atopic dermatitis, and alopecia areata, beyond their current psoriasis treatment.

STRATA's patents specifically cover the combination of UVB light therapy with systemic drugs, JAK inhibitors, and biological drugs, positioning the company at the forefront of integrative dermatologic treatment. The company is also engaged in defensive litigation with LaserOptek, expecting significant damages and injunctive relief.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q2 2025 financial results showing decreased revenue and wider losses. Revenue declined 9% to $7.7 million, with global recurring revenue down 4% to $5.1 million and equipment revenue falling 18% to $2.5 million.

The company reported a net loss of $2.5 million ($0.60 per share) compared to a $0.1 million loss ($0.03 per share) in Q2 2024. Gross profit margin decreased to 56%, with cash position at $6.0 million as of June 30, 2025.

Key developments include historic expansion of CPT codes for skin disease treatments, potentially tripling the covered patient population, and strategic device management with 21 removals and 19 new placements of XTRAC devices. The company achieved near operating cashflow breakeven when adjusting for certain expenses.

STRATA Skin Sciences (NASDAQ: SSKN) is actively working with CMS to accelerate access to expanded reimbursement for its XTRAC® excimer laser treatment ahead of the planned January 1, 2027 implementation. The American Medical Association's CPT Editorial Panel has approved updates to expand reimbursement eligibility to include all inflammatory and autoimmune skin conditions, potentially making treatments accessible by 2026.

This expansion could triple the addressable market to over 30 million patients. Two recent peer-reviewed studies validate the efficacy of combining 308-nm excimer-laser therapy with JAK inhibitors for vitiligo treatment, showing a 100% overall response rate and 96% pigment stability. Additionally, the company provided updates on its ongoing litigation against LaserOptek regarding false advertising claims.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its Q2 2025 earnings release for August 13, 2025 after market close.

The company will host a conference call at 4:30 p.m. ET the same day, featuring management remarks and a Q&A session. Investors can access the call via phone (U.S.: 1-866-524-3160, International: 1-412-317-6760) or through a live webcast. A replay will be available until August 20, 2025, using code 4200962.

STRATA Skin Sciences (NASDAQ: SSKN) announces a significant expansion of CPT codes for its XTRAC® Excimer Laser treatments. The American Medical Association has revised CPT codes 96920-96922 to include multiple inflammatory and auto-immune skin conditions beyond psoriasis. This expansion increases the addressable market from 10 million to over 30 million potential patients, including those with vitiligo (3M), atopic dermatitis (16.5M), and alopecia areata (4.6M). The change eliminates the need for prior authorizations and is expected to reduce systemic denials. Currently, non-psoriasis conditions represent 30% of excimer laser procedures. STRATA's XTRAC platform is present in 1,400 clinics with 4,000 medical providers domestically, with approximately 850 recurring revenue devices in the United States.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q1 2025 financial results with revenue of $6.8 million, up 1% year-over-year. The company's gross margin improved significantly to 53.5%, up 790 basis points from 45.6% in Q1 2024. Global recurring XTRAC® revenue was $4.5 million, with international growth of 27% offsetting a 4% domestic decline. Operating expenses decreased by 5% to $5.7 million, and Adjusted EBITDA improved by $732,000 to negative $547,000. The company's direct-to-consumer strategy showed strong results, with Psoriasis and Acne patient growth of 32% and 128% respectively. International revenue grew 8% in Q1, now representing 36% of total revenue. The company reported a net loss of $2.4 million, or negative $0.58 per share, compared to a loss of $3.4 million in Q1 2024.